We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Athlete’s foot and fungal nail infections aren’t the types of diseases that tend to get investors’ hearts pumping, but that’s not stopping Blueberry Therapeutics. The U.K.-based startup reeled in £10 million ($12.7 million) in series B funding that will,